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Abstract Gastric cancer is the second most common cause of
cancer-related death worldwide, and the incidence of esophageal
adenocarcinoma is rising.While some progress has beenmade in
treatment strategies, overall survival remains very poor for pa-
tients with adenocarcinoma in the upper gastrointestinal tract.
Special AT-rich sequence binding protein 1 (SATB1) is a global
genome organizer that has been demonstrated to promote ag-
gressive tumor behavior in several different types of cancer,
including gastric cancer. The prognostic value of SATB1 expres-
sion in esophageal cancer has, however, not yet been described.
In this study, expression of SATB1 was examined by immuno-
histochemistry on tissue microarrays prepared from tissue sam-
ples from 175 patients with adenocarcinoma of the esophagus,
cardia, or stomach and containing normal tissue, intestinal meta-
plasia, primary tumors, and metastases. A well-validated anti-
body was used. We found SATB1 to be an independent prog-
nostic factor in patients with a radically resected tumor,
correlating with shorter overall survival as well as with shorter
recurrence-free survival. SATB1 expression was also found to be
significantly lower in primary tumors associated with intestinal
metaplasia than those without intestinal metaplasia. This obser-
vation is of potential biological interest as it has been proposed
that intestinal metaplasia-associated tumors constitute a less ag-
gressive phenotype.
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Introduction
Gastric cancer was for a long time the leading cause of cancer-
related death worldwide [1]. Due principally to better living
conditions, the incidence rate has been declining, but gastric
cancer is still the secondmost common cause of cancer-related
death worldwide [1–4] with 5-year survival rates ranging from
10 to 27 % depending on the anatomical location and also on
which part of the world the patient resides in [3]. In contrast,
the incidence of esophageal adenocarcinomas has been steadi-
ly rising in the past decades [2, 5].
With such poor survival rates, there is an evident and imme-
diate need to sharpen our diagnostic, prognostic, and treatment
tools in order to improve survival rates for these patients.When it
comes to treatment, there has been some progress during the last
few years with large studies showing improved survival rates in
patients receiving neoadjuvant or perioperative chemotheraphy
and/or radiotherapy instead of surgical treatment only [6–8].
Although this is a step forward, there has been less progress in
understanding the mechanisms that drive cancer progression and
metastasis in these cancers and in the identification of clinically
useful prognostic and treatment response predictive biomarkers.
Hence, there is a need for novel biomarkers which might
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improve individualized treatment stratification and ultimately
survival of patients with cancer in the upper gastrointestinal tract.
Special AT-rich sequence binding protein 1 (SATB1) is a
global genome organizer [9] initially identified in thymocytes
[10] and that recently attracted some attention as a putative
cancer biomarker. Chromosomes are organized in the nucleus
of a cell in such a way that only part of the genome is expressed
[11]. This is regulated through chromatin proteins involved in
chromatin compaction, which make chromatin fold into three-
dimensional structures which in turn determine which genes
might be transcribed [9]. The genome harbors regions character-
ized by DNA sequences with one strand having A’s, T’s, and C’s
but no G’s (ATC sequences, also known as BURs) [9].When the
ATC sequence context is disrupted bymutations, SATB1binding
is abolished [10]. SATB1 binds specifically to these ATC se-
quences, resulting in chromatin folding into loop domains which
enables regulation of the expression of multiple genes [9, 11].
Furthermore, SATB1 also provides a nuclear platform for
docking of chromatin-remodeling enzymes, and through this
mechanism, coordinates expression of several hundreds up to a
thousand genes [9, 11, 12].
Expression of SATB1 has been correlated with a more
aggressive tumor phenotype and worse prognosis in cancer
of the breast [9, 12], ovary [13], colorectum [14–16], and
larynx [17]. Han et al. suggested that its expression is neces-
sary for breast cancer to become metastatic [12]. Other papers
have reported contradicting results regarding the role of
SATB1 in cancer progression in breast and colorectal cancer
[18–20]. This may be due to differences in experimental
design, e.g., examining SATB1 expression in total RNA tran-
scripts from tumor tissue specimens as opposed to scoring
SATB1 protein levels in individual tumor cells by immuno-
histochemistry [21]. In addition, differences in specificity of
the antibodies used might significantly impact on the results.
SATB1 expression in gastric cancer has previously been
examined in two studies on Chinese populations, both indi-
cating that SATB1 expression is independently associated
with worse prognosis [22, 23]. An in vitro study supported
the correlation between SATB1 expression and aggressive
tumor behavior and also suggested that SATB1 plays a role
in multidrug resistance [24]. SATB1 expression has, to our
best knowledge, not been examined in esophageal cancer. The
aim of our study was to examine longitudinal expression of
SATB1 and its prognostic significance in adenocarcinomas of
the esophagus, cardia, and stomach.
Materials and methods
Study design and participants
The study was performed on a consecutive cohort of 175
patients with adenocarcinoma in the upper gastrointestinal
tract (esophagus, cardia, and stomach) who had been surgi-
cally treated in the university hospitals of Lund and Malmö
from January 1, 2006–December 31, 2010. The cohort has
been described in detail previously [25, 26]. In brief, all
tumors were histopathologically re-examined including con-
firmation of diagnosis, number of lymph nodes with metasta-
sis (re-classified following the standardized TNM 7 classifi-
cation by the American Joint Committee on Cancer (AJCC)
[27]), and presence of intestinal metaplasia (Barrett’s esopha-
gus or gastric intestinal metaplasia (IM)) with or without
dysplasia.
Clinical data, information on recurrence and vital status, or
cause of death were obtained from the medical charts. The
mean follow-up time for patients alive was 5.2 years (range
2.7–7.7).
Patient and tumor characteristics are provided in
Supplemental Table 1.
Approval was obtained from the ethics committee at Lund
University (ref no. 445-07).
Tissue microarrays
Tissue microarrays (TMAs) were constructed using a semi-
automated arraying device (TMArrayer, Pathology Devices,
Westminister, MD, USA) as previously described [25, 28].
Tissue was taken from viable, non-necrotic areas in duplicate
1-mm cores from primary tumors. In addition, lymph node
metastases were sampled in 81 cases, IM (including Barrett’s
esophagus) in 73 cases, normal squamous epithelium in 96
cases, and normal gastric mucosa in 131 cases. Duplicate
cores were obtained from different blocks of the primary
tumor and different lymph node metastases in cases with more
than one metastasis. Normal squamous epithelium and gastric
mucosa were represented in single cores and IM in 1–3 cores.
Antibody validation—Western blot
Western blot analyses were performed according to standard
protocols on SATB1 and SATB2 overexpression lysates co-
expressed with a C-terminal myc-DDK tag (∼3.1 kDa) in
mammalian HEK293T cells (LY427355 and LY414656, re-
spectively, Origene Technologies, Rockville, MD, USA).
Briefly, 2 μl of SATB1 and SATB2 overexpression lysate
was separated on precast 4–20 % CriterionTGX SDS-PAGE
gradient gels (Bio-Rad Laboratories, Hercules, CA) under
reducing conditions, followed by blotting to PVDF mem-
branes (Trans-Blot® Turbo™ Midi PVDF Transfer Packs,
Bio-Rad Laboratories, Hercules, CA), according to the in-
structions of the manufacturer. Membranes were blocked for
45 min at RT in blocking buffer (5 % dry milk, 0.5 % Tween
20, 1× TBS) prior to addition of antibody (anti-SATB1, clone
EPR3895, Epitomics, Burlingame, CA, USA; anti-SATB2
#AMAb90679 CL0320, Atlas Antibodies AB, Stockholm,
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Sweden; or anti-DDK Tag# TA50011, Origene Technologies,
Rockville, MD, USA), diluted to a final concentration of
1 μg/ml in blocking buffer. Following incubation for 1 h with
primary antibody, the membranes were washed 4×5min in 1×
TBS with 0.1 % Tween 20. Horseradish peroxidase (HRP)-
conjugated secondary antibody (swine anti-rabbit antibody
#P0399 or goat anti-mouse antibody #P0447, Dako), diluted
1:3,000 in blocking buffer, was added to the membranes and
incubated for 30 min followed by a final round of washing.
Detection was carried out using chemiluminescence HRP
substrate (Immobilon, EMD Millipore Corporation,
Billerica, MA, USA) according to the manufacturer’s
instructions.
Antibody validation—immunohistochemistry
The specificity of SATB1 and SATB2 antibodies was further
evaluated in immunohistochemical experiments.
Tissue sections (4 μm) were cut from TMAs containing 18
normal (fallopian tube, cervix, endometrium, placenta, testis,
prostate, liver, pancreas, rectum, colon, stomach, duodenum,
small intestine, cerebellum, cerebral cortex, skin, skeletal
muscle, and tonsil) and 7 cancer (prostate, colorectal, ventric-
ular, renal, liver, lung, and breast) tissues. Prior to immuno-
staining, the sections were baked at 50 °C overnight and
deparaffinized in xylene and graded ethanol. Antigen retrieval
was then performed using citrate buffer pH 6 (ThermoFisher
Scientific, Waltham, MA, USA) in decloaking chamber
(Biocare Medical, Walnut Creek, CA, USA). Sections were
stained with anti-SATB1rabbit monoclonal antibody (Clone
EPR3895, Epitomics, Burlingame, CA, USA) diluted 1:100
or mouse monoclona l an t ibody agains t SATB2
(AMAb90679, CL0320, Atlas Antibodies, Stockholm,
Sweden) diluted 1:1,000 in Autostainer 480S (ThermoFisher
Scientific, Waltham, MA, USA) using a commercial kit
(UltraVision LP HRP polymer®, Primary Antibody
Enhancer, Ultra V Block and DAB plus substrate system®,
ThermoFisher Scientific, Waltham, MA, USA). Slides were
counterstained with hematoxylin and mounted using Pertex.
Slides were examined, and images were taken using an
automated system (VSlide, Metasystems).
Immunohistochemistry and staining evaluation
For immunohistochemistry, 4-μm TMA sections were baked
in a heated chamber for 120 min at 60 °C. Antigen retrieval for
Ki67, p53, and SATB1 was performed using HIER pH 9 (PT-
link system Dako, Glostrup, Denmark), and for SATB2 pH 6
(decloaking chamber, Biocare Medical, Walnut Creek, CA,
USA).
For Ki67, a monoclonal antibody (clone MIB1 Dako,
diluted 1:50) was applied in a BenchMark ULTRA (Ventana
Medical systems, Tuscon, AZ, USA).
Expression of p53 was analyzed using a monoclonal anti-
body (clone DO-7, Dako). Expression of SATB1was assessed
using a monoclonal antibody (Clone EPR 3895, Epitomics,
Burlingame, CA, USA, diluted 1:100), as for SATB2
(AMAb90679 CLO320, Atlas Antibodies, diluted 1:1,000),
and staining for all three antibodies was performed in an
Autostainer Plus (Dako, Glostrup, Denmark). DAB was used
as chromogen, and the slides were counterstained with
hematoxylin.
For assessment of Ki67 expression, the fraction of Ki67
nuclear staining was categorized as follows: 0–1, 2–10, 11–
20, 21–50, and >50%. For statistical analysis, three categories
were applied: 0–20, 21–50, and >50 %.
The fraction of p53 staining was categorized as follows: 0–
1, 2–10, 11–50, and >50 %. For statistical analysis, three
categories were applied: 0–1, 2–50, and >50 %.
The estimated fraction of cells with nuclear SATB1 expres-
sion was denoted and after that, transformed into five catego-
ries of 0 (0–1 %), 1 (2–25 %), 2 (26–50 %), 3 (51–75 %), and
4 (>75 %). The predominant nuclear intensity was estimated
as negative (0), weak (1), moderate (2), or strong (3). For
statistical analysis, a combined nuclear score was constructed
by multiplying fraction and intensity, and any intensity of
staining of ≥2 % of the cells was denoted as positive SATB1
staining. In line with previous studies, stromal lymphocytes
served as a positive control for SATB1 [9]. Evaluation of
nuclear SATB2 expression was recorded in the same manner
as described for SATB1.
All stained sections were evaluated by two independent
observers who were blinded to clinical and outcome data.
Statistical analysis
The chi-squared test was applied to analyze the relationship
between SATB1 expression and clinicopathological parame-
ters. Overall survival (OS) rates and recurrence-free survival
(RFS) time according to SATB1 negativity versus SATB1
positivity were calculated using Kaplan-Meier analysis. To
assess differences in the Kaplan-Meier curves, the log-rank
test was used. Unadjusted and adjusted hazard ratios (HR) for
OS and RFS were calculated by Cox regression proportional
hazard modeling. The adjusted model included age, sex, T
stage, N stage, M stage, differentiation, and SATB1
expression.
For some subjects, information on one or several markers
was not available. Missing values were coded as a separate
category for categorical variables. Missing values for categor-
ical variables co-varied. The adjusted model did not converge
due to many constant values. In order to avoid this, only
patients with information on SATB1 expressionwere included
in the adjusted analysis.
Virchows Arch (2014) 465:649–659 651
A backward conditional method was used for variable
selection in the adjusted model.
For all analyses, IBM SPSS Statistics version 20.0 (SPSS
Inc., Chicago, IL, USA) was used. p values <0.05 were
considered significant. All tests were two-sided.
Results
Antibody validation
Western blot analyses were performed on HEK293T cell
lysates overexpressing the full-length SATB1 and SATB2
proteins (Fig. 1a–c) and revealed that both antibodies bind
specifically and selectively to their respective target protein.
Different staining patterns for SATB1 and SATB2 were
obtained on normal and cancer tissues. SATB1 immunoreac-
tivity was limited to a subpopulation of lymphoid cells in
various tissues (Fig. 1d, f), but no immunoreactivity was
observed in glandular cells in the rectum (Fig. 1d), colon,
or in colorectal cancer (data not shown). In addition, weak
to moderate nuclear staining was seen in single cells in
the fallopian tube, seminiferous tubules, and in the major-
ity of glandular cells in prostate. Strong nuclear immuno-
reactivity was detected in single neurons in cerebral
cortex.
Very strong immunoreactivity for SATB2 was observed in
colorectal mucosa (Fig. 1e) as well as in colorectal cancer
(data not shown). Moderate nuclear positivity was seen in a
subset of neurons in cerebral cortex and single glandular cells
in the duodenum, kidney, and prostate. In tonsil, only single
lymphoid cells displayed very weak nuclear immunoreactivity
(Fig. 1g).
Taken together, IHC and Western blot validation demon-
strates that the two antibodies used in this study are highly
specific to their respective target protein, despite extensive
sequence similarity of the two proteins.
Longitudinal SATB1 expression
SATB1 could be evaluated in 71/96 (74 %) samples with
normal squamous epithelium, 125/131 (95 %) samples
with normal gastric mucosa, 63/73 (86 %) samples with
IM, 170/175 (97 %) primary tumors, and 79/81 (98 %)
metastases. Immunohistochemical images are shown in
Fig. 2.
As demonstrated in Fig. 3a, SATB1 expression was signif-
icantly higher in primary tumors (n=53/170, 31.2 %) and
metastases (n=32/79, 40.5 %) than in normal squamous epi-
thelium (n=0/96, 0 %) and normal gastric mucosa (n=0/131,
0 %) where no expression was seen. SATB1 expression did
not differ between the primary tumors and metastases (p=
0.116). SATB1 expression was significantly higher in IM than
that in normal tissue (p=0.003), but the number of SATB1-
expressing IM samples was very small (n=8). Figure 3b
shows that the expression of SATB1 was significantly
lower in primary tumors with tumor-associated IM than
that in primary tumors without tumor-associated IM (p=
0.031), but this difference was not maintained in
metastases.
Correlations of SATB1 expression in primary tumors
with clinicopathological parameters
Table 1 lists the distribution of clinicopathological and inves-
tigative parameters according to SATB1 expression.
Significant associations of SATB1 expression were found
with younger age (p=0.045) and more advanced N stage
(p=0.010). SATB1 expression was also significantly more
common in esophageal compared to cardiac or gastric cancer
(p=0.033).
Impact of SATB1 expression on survival
Kaplan-Meier analysis of radically resected (R0) tumors re-
vealed both decreased OS (p=0.033) and shorter RFS (p=
0.021) for patients with SATB1-positive compared to SATB1-
negative tumors (Fig. 4). SATB1expression was significantly
associated with shorter RFS in patients with a R0 tumor and
distant metastasis-free (M0) disease (p=0.008) but not with
OS.
As demonstrated in Table 2, the prognostic value of SATB1
was confirmed in unadjusted Cox regression analysis for OS
in patients with R0 resection (HR=1.74; 95 % CI 1.04–2.90,
p=0.036) and for RFS in patients with R0 resection/M0
disease (HR=2.53; 95 % CI 1.24–5.16, p=0.011). These
associations remained significant in adjusted analysis (HR=
2.30; 95 % CI 1.32–4.01, p=0.003 for OS and HR=3.88;
95 % CI 1.72–8.72, p=0.001 for RFS), and also when tumor
location was included in the adjusted model (data not shown).
In the entire cohort, SATB1 positivity was not significantly
associatedwith overall survival but with a significantly shorter
RFS in unadjusted (HR=1.68; 95 % CI 1.04–2.71, p=0.032)
but not in adjusted analysis (data not shown).
As shown in Supplemental Fig. 1, SATB2was expressed to
a very limited extent in the examined tissues. No correlation
with RFS or OS was seen (data not shown), and hence, no
further statistical analyses were performed. Expression of
Ki67 and p53 in primary tumors and metastases had no
prognostic significance (data not shown). Kaplan-Meier anal-
ysis revealed a trend toward longer OS for patients with
tumor-adjacent IM compared with patients without tumor-
adjacent IM (p=0.054, data not shown). Patients with R0
tumors had a prolonged OS compared with patients with
non-R0 tumors (p=<0.001, data not shown).
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Discussion
We have examined the expression of SATB1 in matched
normal squamous epithelium, normal gastric mucosa,
Barrett’s esophagus, gastric intestinal metaplasia, and primary
and metastatic adenocarcinoma in patients with cancer of the
upper gastrointestinal tract with known clinical outcome. We
show that SATB1 expression in primary tumors is an inde-
pendent prognostic marker for shorter OS and shorter RFS in
patients with radically resected tumors. These results are in
line with several previous studies indicating that SATB1 ex-
pression correlates with a more aggressive phenotype and
worse prognosis in several types of cancer [9, 12–16].
In our cohort, involvement of resection margins was sig-
nificantly associated with poor prognosis. This not only val-
idates the use of the cohort for biomarker studies but also
strengthens the prognostic value of SATB1 expression in
radically resected tumors, in particular since an earlier study
was limited by a lack of information on residual tumor after
surgery [13]. SATB1 expression was prognostic for both OS
Fig. 1 Assessment of specificity
of anti-SATB1 and anti-SATB2
antibodies using Western blot (a–
c) and immunohistochemistry (d–
e) analyses. Western blot results
following incubation with anti-
SATB1 (a), anti-SATB2 (b), or
anti-DDK Tag (c) antibodies (lane
1, molecular weight marker; lane
2, negative control lysate; lane 3,
SATB1; and lane 4, SATB2-
overexpressing mammalian
HEK293T lysate). Note specific
binding of antibodies to their
respective lysates.
Immunohistochemistry results
following staining with anti-
SATB1 (d, f) and anti-SATB2 (e,
g) antibodies in rectum (d, e) and
tonsil (f, g). Note strong nuclear
immunoreactivity in a subset of
lymphocytes following staining
with anti-SATB1 antibody both in
rectum and tonsil and absence of
nuclear immunoreactivity in
glandular epithelium of rectum.
Staining with anti-SATB2
displays strong nuclear positivity
in rectum glandular cells, while
lymphoid cells are mainly
negative
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Fig. 2 Examples of immunohistochemical SATB1 staining. Images (×10
magnification) of SATB1 expression in different tissue entities from three
cases. From left to right (a) low- and high-grade dysplastic intestinal
metaplasia (score 4), cancer (score 0), and metastasis (score 0 but with
SATB1-positive lymphocytes) in a T2N2M0 esophageal cancer; (b)
intestinal metaplasia (score 1), cancer (score 4), and metastasis (score 9)
in a T3N1M0 cardiac cancer; (c) normal squamous epithelium (score 0),
cancer (score 12), and metastasis (score 12) in a T3N3M0 cardiac cancer
Fig. 3 Visualization of SATB1 expression according to tissue type. a SATB1 expression according to tissue type in the entire cohort. b SATB1
expression in primary tumors (left) and metastases (right) with and without the presence of intestinal metaplasia (Barrett’s esophagus included)
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and RFS in R0 tumors only when all R0 tumors were includ-
ed. When R0 tumors with distant metastasis (M1) were ex-
cluded, SATB1 was only significantly associated with OS, but
this might change with a longer follow-up time. SATB1
expression was not different between primary tumors and
metastases, indicating that it is sufficient to examine only the
primary tumor for prognostic purposes.
We evaluated SATB1 expression using an approach similar
to that used in a previous study [22]. As in previous studies,
we found that lymphocytes are suitable as internal positive
control [9, 18]. We also confirm that expression of SATB1in a
limited fraction of the tumor cells already confers poor prog-
nosis [12].
The prognostic value of SATB1 is controversial in different
tumor types, whichmay be due to tissue-dependent regulatory
functions of SATB1 [18]. Possible implications of differences
in methodologies and materials also need to be considered,
notably the possibility of discordance between messenger
R N A ( m R N A ) a n d p r o t e i n l e v e l s [ 2 9 ] .
Immunohistochemistry (IHC) allows assessment of protein
expression of a putative biomarker in specific cell types and
even its subcellular location. Our results are in line with those
reported by Han et al., in that expression of SATB1 protein
independently predicts worse outcome [12]. Studies on
SATB1mRNA levels failed to demonstrate independent prog-
nostic value for SATB1 expression [19, 20]. Such mRNA
studies usually include both tumor and normal cells, which
is an inherent source of error. For biomarker studies therefore,
IHC is a more reliable method of investigation. The use of
different antibodies is another potential source of controversy.
SATB1 is highly homologous to SATB2 and the specificity of
SATB1 and SATB2 antibodies has been questioned in previ-
ous studies [18]. The specificity of antibodies for SATB1 and
SATB2 needs to be thoroughly validated [9], as we have
performed in this study. This is all the more important as
Table 1 Distribution of clinicopathological characteristics according to
SATB1 expression
SATB1 expression







Median (range) 72.9 (42.6–94.4) 65.6 (48.2–87.2)
Sex 0.492
Women 30 (25.6) 11 (20.8)
Men 87 (74.4) 42 (79.2)
T stage 0.243
1 11 (9.6) 7 (13.2)
2 28 (24.6) 4 (7.5)
3 58 (50.9) 32 (60.4)
4 17 (14.9) 10 (18.9)
Unknown 3 0
N stage 0.010
0 47 (40.2) 9 (17.0)
1 18 (15.4) 12 (22.6)
2 26 (22.2) 14 (26.4)
3 26 (22.2) 18 (34.0)
Unknown 0 0
M stage 0.288
0 93 (86.9) 40 (93.0)
1 14 (13.1) 3 (7.0)
Unknown 10 10
Differentiation grade 0.853
High 3 (3.0) 3 (6.4)
Intermediate 28 (28.3) 11 (23.4)





No 105 (92.9) 43 (87.8)
Yes, with oxaliplatin 1 (0.9) 1 (2.0)
Yes, without
oxaliplatin
4 (3.5) 4 (8.2)
Yes, NOS 3 (2.7) 1 (2.0)
Unknown 4 4
Location 0.033
Esophageal 33 (29.2) 26 (49.1)
Cardiac 34 (30.1) 11 (20.8)
Gastric 46 (40.7) 16 (30.2)
Unknown 4 0
Ki67 expression 0.201
0–20 % 43 (37.1) 13 (24.5)
21–50 % 33 (28.4) 19 (35.8)
>50 % 40 (34.5) 21 (39.6)
p53 expression 0.059
0–1 % 37 (31.6) 11 (20.8)
Table 1 (continued)
SATB1 expression





2–50 % 30 (25.6) 11 (20.8)
>50 % 50 (42.7) 31 (58.5)
Missing 1 0
SATB2 expression <0.001
SATB2-negative 109 (93.2) 38 (71.7)
SATB2-positive 8 (6.8) 15 (28.3)
Resection margin 0.271
R0 82 (70.1) 37 (69.8)
R1 27 (23.1) 6 (11.3)
R2 8 (6.8) 10 (18.9)
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several studies have indicated that SATB1 and SATB2 have
antagonistic qualities [9, 14, 30]. As an example, SATB2
expression was a favorable prognostic marker in colorectal
cancer [30, 31].
SATB1 remained significant as a prognostic factor when
tumor location was included in the adjusted Cox regression
model, indicating that SATB1 is prognostic in upper gastroin-
testinal tract cancer regardless of its anatomical location.
Interestingly, SATB1 expression was significantly lower in
primary tumors associated with IM than in primary tumors not
associated with IM. This is in line with at least two different
pathways of gastroesophageal carcinogenesis, one intestinal
(arising from dysplasia in IM) and one non-intestinal (arising
from cardia-type mucosa), the former being associated with
better overall survival [32]. Our cohort showed a similar trend,
which is in agreement with SATB1 expression as a negative
prognostic factor.
ERBB2 (HER2) is an important drug target in breast cancer
and an increasingly important target in gastric cancer [8].
SATB1 upregulates ERBB2 (HER2) expression [9, 12],
which draws attention to SATB1 as a candidate drug target.
Knockdown of SATB1 in aggressive breast cancer cell lines
Fig. 4 Kaplan-Meier estimates of survival and recurrence according to
SATB1 expression. Overall survival (a) and recurrence-free survival (b),
according to SATB1 expression in patients with radically resected tumors.
Overall survival (c) and recurrence-free survival (d) in patients with
radically resected tumors and distant metastasis-free disease
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caused complete reversal of tumor growth and metastatic
abilities in vivo and introduction of SATB1 decoy DNA
drastically reduced invasive and metastatic capacity of
SATB1-positive cell lines [33]. Similar results were reported
in colorectal cancer [9, 12, 16]. SATB1 downregulates expres-
sion of E-cadherin, which is a characteristic event in epithelial
to mesenchymal transition and an important step in invasion
and metastasis [34, 35].
Studies, using the same well-validated anti-SATB1 anti-
body as in our study, have indicated that SATB1 contributes to
chemotherapy multidrug resistance [24], which provides ad-
ditional arguments in favor of SATB1-blocking as a novel
therapeutic approach.
None of the patients in this study had received neoadjuvant
treatment. This rules out any possibility that biomarker ex-
pression was affected by treatment, which must be considered
a strength of this study. A further strength is that all available
surgically treated tumors were included consecutively, which
excludes risk of selection bias. A limitation of the present
study is the use of TMAs with a risk of sampling bias. Our
TMA design limits this as duplicate cores were taken from
different blocks of the primary tumor and different lymph
node metastases in cases with more than one metastasis.
Furthermore, even with full-face sections, sampling bias is
not excluded as these also represent only a limited fraction of
the tumor. An advantage of the TMA approach is the high
number of tumors that can be studied, which conceivably
might compensate for false negative or positive tissue cores
[36].
In conclusion, we show that SATB1 is an independent
prognostic biomarker in patients with radically resected ade-
nocarcinomas of the upper gastrointestinal tract.
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